<DOC>
	<DOCNO>NCT01657487</DOCNO>
	<brief_summary>This study investigate compare treatment efficacy high medium dose fluticasone combination salmeterol COPD patient .</brief_summary>
	<brief_title>Comparing Treatment Efficacy With High Medium Dose Fluticasone Combination With Salmeterol COPD Patients</brief_title>
	<detailed_description>Diagnosis criterion inclusion exclusion : Inclusion : 1 . Male female outpatient age 40 years≧ 2 . Current ex-smoker , smoke history 10 pack≧- year 3 . COPD ( FEV1/FVC &lt; 70 % ) patient post-bronchodilator FEV1 70 % ≦predicted value , without bronchial reversibility ( 10 % increase post ≦bronchodilator ) Exclusion : 1 . Diagnosis suspicion sleep apnea . 2 . Concurrent rhinitis , eczema , asthma . 3 . Clinically overt bronchiectasis , lung cancer , active tuberculosis , know specific pulmonary disease . 4 . A chest X-ray indicate diagnosis COPD might interfere study . 5 . Major disease abnormality uncontrolled therapy . 6 . Alcohol medication abuse . 7 . Patients low respiratory tract infection receive systemic steroid 4 week prior commencement study . 8 . Unable unwilling comply protocol Test product : fluticasone125 mcg/salmetrol 25 mcg ( Seretide 125 Evohaler ) fluticasone250 mcg/salmetrol 25 mcg ( Seretide 250 Evohaler ) Formulation : fluticasone/salmeterol , 125/25 mcg/puff Dose : 2 puff bid</detailed_description>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>1 . Male female outpatient age 40 years≧ 2 . Current exsmoker , smoke history 10 pack≧ year 3 . COPD ( FEV1/FVC &lt; 70 % ) patient postbronchodilator FEV1 70 % ≦predicted value , without bronchial reversibility ( 10 % increase post ≦bronchodilator ) 1 . Diagnosis suspicion sleep apnea . 2 . Concurrent rhinitis , eczema , asthma . 3 . Clinically overt bronchiectasis , lung cancer , active tuberculosis , know specific pulmonary disease . 4 . A chest Xray indicate diagnosis COPD might interfere study . 5 . Major disease abnormality uncontrolled therapy . 6 . Alcohol medication abuse . 7 . Patients low respiratory tract infection receive systemic steroid 4 week prior commencement study . 8 . Unable unwilling comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>Fluticasone/Salmeterol</keyword>
	<keyword>high dose</keyword>
</DOC>